IsoPlexis Stock

isoplexis.comHealthcare / BioTech & PharmaFounded: 2013Funding to Date: $161.52MM

IsoPlexis is building solutions to accelerate the development of curative medicines and personalized therapeutics.

Register for Details

For more details on financing and valuation for IsoPlexis, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for IsoPlexis.

Register Today

Other companies like IsoPlexis in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B

News Highlights

IsoPlexis Preliminary Q1 Revenues Rise up to 52 Percent; Firm Cuts 20 Percent of Workforce
The newly public provider of single-cell analysis technologies said that the reorganization would help extend its cash runway into the second half of 2024.
People in the News: New Appointments at NeoGenomics, Mainz Biomed, IsoPlexis, More
IsoPlexis Using IPO Funds to Support Move Into Transcriptomics, Metabolomics
The firm is expanding beyond single-cell proteomics with new data types that could help it move into research areas outside its traditional immune profiling focus.
Updated on: Oct 2, 2023

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.